Table 4.

Advanced combining therapies on BRAF-mutated mCRC

Therapeutic strategy	Agents investigated	PFS in the experiment group (months)	PFS in the control group (months)
Combining BRAF and EGFR inhibitors	Vemurafenib + panitumumab	3.2	∼2 months (standard therapies); 2.1 (singlet BRAF inhibitor)
	Dabrafenib + panitumumab	3.5
	Encorafenib + cetuximab	3.7
Combining BRAF and MEK inhibitors	Dabrafenib + trametinib	3.5
Combining EGFR and MEK inhibitors	Panitumumab + trametinib	2.6
Combining BRAF, EGFR, and MEK inhibitors	Dabrafenib + trametinib + panitumumab	4.2	2.6/3.5
	Encorafenib + cetuximab + binimetinib	4.3	1.5